Update on emerging biomarkers in lung cancer
There has been considerable progress made in identifying oncogenic driver mutations in
advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is
comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make
treatment decisions. These mutations are clinically important as available targeted therapies can achieve
significant responses and prolonged disease control. This review will summarize the current guidelines for
biomarker testing and available therapeutic agents.
No comments:
Post a Comment